SCHEMBL710678

SCHEMBL710678

Cc1ccc(C(=O)Nc2ccc(OC(C)C)c(-c3nc4cccnc4[nH]3)c2)o1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RAB9A P51151 5/20 0.42
NPC1 O15118 4/20 0.42
NR0B1 P51843 1/20 0.42
KLK7 P49862 1/20 0.42
SMN1; SMN2 Q16637 4/20 0.41
HTT P42858 2/20 0.41
MAPT P10636 6/20 0.41
HPGD P15428 3/20 0.41
LMNA P02545 1/20 0.41
PKM P14618 5/20 0.39
TP53 P04637 3/20 0.39
POLB P06746 3/20 0.39
ALDH1A1 P00352 3/20 0.39
TDP1 Q9NUW8 2/20 0.39
TSHR P16473 2/20 0.39
HSD17B10 Q99714 2/20 0.39
NFKB1 P19838 1/20 0.39
NFKB2 Q00653 1/20 0.39
RELA Q04206 1/20 0.39
MEN1 O00255 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL713520 0.82 MEN1 (0.47) HTTMAPTALDH1A1MEN1KMT2A
SCHEMBL711284 0.81 RORC (0.44) RAB9ANPC1SMN1; SMN2HTTMAPT
SCHEMBL713378 0.74 CBFB (0.36) NPC1SMN1; SMN2HPGDLMNATP53
SCHEMBL711187 0.71 CYP3A4 (0.46) RAB9ANPC1
Trifluoroacetic Acid SCHEMBL711385 0.70 CYP3A4 (0.39) RAB9ASMN1; SMN2HPGDALDH1A1HSD17B10
SCHEMBL711230 0.70 IP6K1 (0.37) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL711229 0.70 IP6K1 (0.37) RAB9ANPC1MAPTMEN1KMT2A
SCHEMBL9071892 0.70 CYP3A4 (0.37) MAPT
SCHEMBL10206656 0.70 PDE4A (0.41)
SCHEMBL9071890 0.69 MAOA (0.42) HPGDPOLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-8124617-B2 Imidazopyridine compounds TAKEDA SAN DIEGO, INC. (US) 2012-02-28 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS TAKEDA SAN DIEGO, INC. 2010-03-18 US disclosed
EP-1940837-A2 IMIDAZOPYRIDINE COMPOUNDS Takeda Pharmaceutical Company Limited (JP) 2008-07-09 EP disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed
WO-2007028135-A2 IMIDAZOPYRIDINE COMPOUNDS TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-03-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100069431-A1 IMIDAZOPYRIDINE COMPOUNDS GCK, GCKR, KHK RAB9A 3465/4885NPC1 3486/4885NR0B1 4071/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.